“1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 9
2 Pharmaceuticals & Healthcare, Global, Deal Summary 12
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, September 2015 12
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, September 2015 14
2.2.1 Gilead Sciences Raises USD10 Billion in Public Offering Notes 14
2.2.2 Biogen Raises USD6 Billion in Public Offering Notes 14
2.2.3 Concordia Healthcare Acquires Amdipharm Mercury for USD3.54 Billion 15
2.2.4 Sanofi Prices Public Offering of Notes for USD2.3 Billion 16
2.2.5 Amgen Enters into Licensing Agreement with Xencor 16
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, September 2015 18
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, September 2015 19
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20
3.1 Pharmaceuticals & Healthcare, Global, M&A, September 2015 20
3.1.1 Top M&A Deals in September 2015 21
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, April 2015 – September 2015 22
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, September 2015 24
3.2.1 Top Equity Offering Deals in September 2015 25
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, April 2015 – September 2015 26
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, September 2015 28
3.3.1 Top PE/VC Deals in September 2015 29
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, September 2015 30
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, September 2015 31
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, April 2015-September 2015 33
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, April 2015-September 2015 34
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, September 2015 35
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, September 2015 35
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, April 2015 – September 2015 37
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), September 2015 38
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, September 2015 39
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), April 2015 – September 2015 40
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, April 2015 – September 2015 42
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), April 2015 – September 2015 43
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), April 2015 – September 2015 45
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, September 2015 47
5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, September 2015 47
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2015 49
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), April 2015 – September 2015 51
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), April 2015 – September 2015 53
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), April 2015 – September 2015 55
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), April 2015 – September 2015 57
5.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, September 2015 58
5.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, September 2015 59
5.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, September 2015 60
6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 61
6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, September 2015 61
6.1.1 Oncology – Deals of the Month 62
6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, September 2015 64
6.2.1 Central Nervous System – Deals of the Month 65
6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, September 2015 67
6.3.1 Infectious Diseases – Deals of the Month 68
6.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, September 2015 71
6.4.1 Cardiovascular – Deals of the Month 72
6.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, September 2015 74
6.5.1 Immunology – Deals of the Month 75
6.6 Pharmaceuticals & Healthcare, Global, Respiratory Deals, September 2015 77
6.6.1 Respiratory – Deal of the Month 78
6.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, September 2015 79
6.7.1 Metabolic Disorders – Deal of the Month 80
7 Deal Summary by Geography 82
7.1 Pharmaceuticals & Healthcare, North America Deals, September 2015 82
7.1.1 North America – Deals of the Month 83
7.2 Pharmaceuticals & Healthcare, Europe, Deals, September 2015 86
7.2.1 Europe – Deals of the Month 87
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, September 2015 89
7.3.1 Asia-Pacific – Deals of the Month 90
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, September 2015 92
7.4.1 Rest of the World – Deals of the Month 93
8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 94
8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, April 2015 – September 2015 94
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, April 2015 – September 2015 96
9 Further Information 98
9.1 Methodology 98
9.2 About GlobalData 99
9.3 Disclosure information 100
9.4 Disclaimer 100″
“1.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 13
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, September 2015 14
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), September 2015 19
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 21
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, September 2015 21
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, April 2015 – September 2015 23
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 25
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, September 2015 25
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 27
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 29
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, September 2015 29
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, April 2015 – September 2015 30
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), September 2015 32
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 33
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, April 2015 – September 2015 34
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 36
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 37
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2015 – September 2015 38
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), September 2015 39
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), April 2015 – September 2015 41
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2015 – September 2015 44
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), April 2015 – September 2015 46
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 48
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), April 2015 – September 2015 50
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 52
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), September 2015 54
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2015 – September 2015 56
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), September 2015 58
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, September 2015 58
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, September 2015 59
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, September 2015 60
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 62
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 65
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 68
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 72
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 75
Table 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 78
Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 80
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 83
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 87
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 90
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 93
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 95
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 97″
“1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 12
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), September 2015 18
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), September 2015 19
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 20
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, April 2015 – September 2015 22
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 24
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 26
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 28
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, April 2015 – September 2015 30
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), September 2015 31
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), September 2015 32
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 33
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 35
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 37
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2015 – September 2015 38
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), April 2015 – September 2015 40
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2015 – September 2015 42
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, April 2015 – September 2015 43
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), April 2015 – September 2015 45
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 47
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2015 – September 2015 49
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 51
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), April 2015 – September 2015 53
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, April 2015 – September 2015 55
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), April 2015 – September 2015 56
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), September 2015 57
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 61
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 64
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 67
Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 71
Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 74
Figure 32: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 77
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 79
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 82
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 86
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 89
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 92
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 94
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), April 2015 – September 2015 96″